F. No. 12(7)/2021/DP/NPPA/Div.II/ Vol-VI

National Pharmaceutical Pricing Authority

Subject: Minutes of the 63rd meeting of the Multidisciplinary Committee of Experts held on 22.10.2024 at 11:30 AM.

63rd meeting of the Multidisciplinary Committee of Experts was held on 22.10.2024 at 11:30 AM under the convenorship of Shri Sanjay Kumar, Advisor (Cost). The following members attended the meeting: -

1. Shri Ranga Chandrashekar, Joint Drugs Controller, CDSCO
2. Dr. Rakesh Kr. Singh, Associate Professor, NIPER Raebareli, through Video Conferencing
3. Dr. Jai Prakash, Indian Pharmacopoeia Commission – Co-opted member, through Video Conferencing
4. Prof. Y. K. Gupta, Principal Scientific Advisor (Projects), THSTI-DBT, GoI & Ex-HoD, Pharmacology & Dean (Academics), AIIMS, New Delhi – Co-opted member, through Video Conferencing

The following officers of NPPA attended and presented the cases before the Committee:

1. Ms. Rashmi Tahiliani, Director (Pricing)
2. Ms. Yuvika Panwar, Assistant Director (Pricing)

Agenda Item No. 1: Application filed by M/s Cipla Limited vide their letter dated 15.02.2024 for grant of separate price/special price for 'Ciphaler inhaler device' under the provision of Para 11(3) of DPCO, 2013.

1.1 The committee noted that the matter was deliberated in 59th meeting held on 08.05.2024 and 60th meeting held on 26.06.2024, wherein it was directed to seek clarification from CDSCO regarding the licensing requirement of the drug device combination and their applicability to the 'Ciphaler', i.e., whether the company is required to take a fresh approval of the Drug Device combination from CDSCO and State Licensing Authority or the approval for the FDC of drugs alone as provided by the applicant would be applicable in the instant case. Accordingly, letter dated 09.07.2024 was sent to CDSCO seeking clarification regarding the CDSCO approval of Cipla's Ciphaler Device. The Committee noted that so far, no communication in this regard has been received from the CDSCO.

1.2 The Committee was informed that M/s Cipla Limited vide email dated 26.09.2024 has requested to withdraw the application dated 15.02.2024. The Committee noted the withdrawal request of M/s Cipla Limited and recommended that the matter may be closed.

Agenda Item No. 2: Application by M/s Pulse Pharmaceuticals Private limited for exemption from the provisions of Drug Price Control Order 2013 under Para 32 (iii) for the formulation "Paracetamol Oral solution (taste masked) 125mg/5ml and 250mg/5ml produced utilizing indigenously developed innovative LYOMATRIX Technology offering Novel Drug Delivery System".

2.1 The Committee noted that M/s Pulse Pharmaceuticals Private Limited has submitted application for exemption under Paragraph 32 (iii) for their formulation, "Paracetamol Oral Solution (taste masked) 125mg/5ml and 250mg/5ml," claiming that the formulation has been developed utilizing the indigenously developed LYOMATRIX Technology, involving a Novel Drug Delivery System.

2.2 The Committee noted the applicant has claimed exemption under Para 32(iii) citing various benefits like unmet medical need, the innovative LYOMATRIX technology, faster absorption indicated by bioequivalence studies, clinical trial demonstrating quicker temperature reduction, and higher acceptability compared to existing products in terms of taste, smell, and mouthfeel. It was also noted that the applicant claimed high efficacy, reduced dosage frequency for pharmacoeconomic advantages.

2.3 The Committee recalled the deliberations held in 62nd meeting held on 25.09.2024 wherein it was directed that M/s Pulse Pharmaceuticals Private Limited may make presentation in the next MDC meeting. Accordingly, M/s Pulse Pharmaceuticals Private Limited made a presentation before the committee.

2.4 The Committee deliberated upon the matter and observed that there is no significant difference in the formulation as manufactured by M/s Pulse Pharmaceuticals Private Limited and the conventional paracetamol oral liquid with respect to faster absorption as mentioned by the company. The Committee observed that the firm has carried out bioequivalence (BE) study with a comparator on small number of subjects and as per the firm the AUC is similar to the reference product and accordingly the BE of the applied product is non-inferior with the reference product. Although the company mentioned that its product is taste masked and is more palatable compared to conventional formulation, it did not provide any evidence in support of the same and could not justify its stand before the committee during the presentation. Committee also observed that 100% temperature reduction with single dose is hypothetical.

2.5 The Committee noticed that the delivery system as developed by the company does not fall under the definition of 'New Drug Delivery System' as solutions are covered under oral liquid dosage forms which are already in existence. Further, other formulations are also available that are taste masked. Accordingly, the committee recommended that the proposal does not qualify under the provisions of Para 32 of the DPCO for exemption from price control.

Agenda Item No. 3: Application for extension of ceiling price of I V fluids (Double Port) for their product "JEDUX DOUBLE PORT WITH EURO HEAD, JPORT PLUS" with packaging in non-glass with special feature filed by M/s Jedux Parenteral Private Limited.

3.1 The Committee noted that M/s Jedux Parenteral Private Limited vide letter dated 27.08.2024 has applied for extension of separate ceiling price of IV fluids (Double Port) under (JEDUX DOUBLE PORT WITH EURO HEAD, JPORT PLUS) with packaging in non-glass with special feature for the formulations as mentioned in the Table below:

Sr. No.	Name of Product	Composition Each 100ml	Pack Size
1.	Dextrose Injection IP 5% w/v	Dextrose Anhydrous IP 5gm, Water for injections IP q.s.	500ml & 1000ml
2.	Dextrose Injection IP 10% w/v	Dextrose Anhydrous IP 10gm, Water for injections IP q.s.	500ml & 1000ml
3.	Sodium Chloride 0.9% & Dextrose Injection 5% w/v	Sodium Chloride IP 0.9gm, Dextrose Anhydrous IP 5gm, Water for injections IP q.s.	500ml & 1000ml
4.	Sodium Chloride Injection IP 0.9% w/v	Sodium Chloride IP 0.9gm, Water for injections IP q.s.	100ml. 500ml & 1000ml
5.	Ringer Lactate Solution for Injection IP	Sodium Chloride IP 0.6gm, Potassium Chloride IP 0.04gm, Calcium Chloride IP 0.027gm, Sodium Lactate USP 0.32gm. Water for injection IP q.s.	500ml & 1000ml
6.	Mannitol Injection IP 20% w/v	Mannitol IP 20gm, Water for injections IP q.s.	100ml
7.	Ciprofloxacin Injection IP	Sodium Chloride IP 0.9gm, Ciprofloxacin Lactate eq. to Ciprofloxacin 0.2gm, Water for injections IP q.s.	100ml
8.	Metronidazole Injection IP	Metronidazole IP 0.5gm, Sodium Chloride IP 0.8gm, Water for injections IP q.s.	100ml
9.	Dextrose Injection IP 25% w/v	Dextrose Anhydrous IP 25gm, Water for injections IP q.s.	100ml & 500ml

3.2 The Committee recalled the deliberations held in 62nd meeting held on 25.09.2024, wherein the company was directed to submit the following documents and also give the demonstration of its products:

a. Test report of three consecutive batches for plastic granules used as per IP standards
b. Detailed flow rate analysis of more than one bottle from each batch along with standard deviation, if any, in data in respect of each formulation
c. Report on residual quantity after administration in respect of the IV fluids of each formulation

3.3 The company demonstrated its products before the Committee. The company also stated that it is withdrawing its application seeking separate ceiling price in respect of Dextrose Injection IP 10% w/v in 500 ml and 1000 ml pack.

3.4 The Committee noted the special features of the products demonstrated by M/s Jedux Parenteral Private Limited i.e., the packaging in non-glass container with special features such as dual port, self-collapsibility, self sealability, no air vent and no chances of contamination during manufacture, infusion and admixing.

3.5 The Committee also examined the data submitted during the meeting relating to flow rate analysis, certificate of analysis for plastic used in manufacturing of the plastic containers and the residual quantity in the containers. The Company also confirmed that the specifications of plastic used in manufacturing of the plastic containers are as per IP 2022.

3.6 The Committee deliberated upon the matter and recommended the extension of separate ceiling prices for M/s Jedux Parenteral Private Limited for the below mentioned formulations:

Sr. No.	Name of Product	Composition Each 100ml	Pack Size	Applicable Ceiling Price / Unit	S.O. No. & Date
1.	Dextrose Injection IP 5% w/v	Dextrose Anhydrous IP 5gm, Water for injections IP q.s.	500ml	82.27 per pack	1552(E) dt. 26.03.2024
2.	Dextrose Injection IP 5% w/v	Dextrose Anhydrous IP 5gm, Water for injections IP q.s.	1000ml	95.11 per pack	1552(E) dt. 26.03.2024
3.	Sodium Chloride 0.9% & Dextrose Injection 5% w/v	Sodium Chloride IP 0.9gm, Dextrose Anhydrous IP 5gm, Water for injections IP q.s.	500ml	85.52 per pack	1552(E) dt. 26.03.2024
4.	Sodium Chloride 0.9% & Dextrose Injection 5% w/v	Sodium Chloride IP 0.9gm, Dextrose Anhydrous IP 5gm, Water for injections IP q.s.	1000ml	99.94 per pack	1552(E) dt. 26.03.2024
5.	Sodium Chloride Injection IP 0.9% w/v	Sodium Chloride IP 0.9gm, Water for injections IP q.s.	100ml	42.06 per pack	1552(E) dt. 26.03.2024
6.	Sodium Chloride Injection IP 0.9% w/v	Sodium Chloride IP 0.9gm, Water for injections IP q.s.	500ml	87.94 per pack	1552(E) dt. 26.03.2024

Sr. No.	Name of Product	Composition Each 100ml	Pack Size	Applicable Ceiling Price / Unit	S.O. No. & Date
7.	Sodium Chloride Injection IP 0.9% w/v	Sodium Chloride IP 0.9gm, Water for injections IP q.s.	1000ml	98.51 per pack	1552(E) dt. 26.03.2024
8.	Ringer Lactate Solution for Injection IP	Sodium Chloride IP 0.6gm, Potassium Chloride IP 0.04gm, Calcium Chloride IP 0.027gm, Sodium Lactate USP 0.32gm. Water for injection IP q.s.	500ml	64.96 per pack	1553(E) dt. 26.03.2024
9.	Ringer Lactate Solution for Injection IP	Sodium Chloride IP 0.6gm, Potassium Chloride IP 0.04gm, Calcium Chloride IP 0.027gm, Sodium Lactate USP 0.32gm. Water for injection IP q.s.	1000ml	114.21 per pack	1553(E) dt. 26.03.2024
10.	Mannitol Injection IP 20% w/v	Mannitol IP 20gm, Water for injections IP q.s.	100ml	0.40 per ML	1556(E) dt. 26.03.2024
11.	Ciprofloxacin Injection IP	Sodium Chloride IP 0.9gm, Ciprofloxacin Lactate eq. to Ciprofloxacin 0.2gm, Water for injections IP q.s.	100ml	0.23 per ML	2286(E) dt. 14.06.2024
12.	Metronidazole Injection IP	Metronidazole IP 0.5gm, Sodium Chloride IP 0.8gm, Water for injections IP q.s.	100ml	0.25 per ML	1555(E) dt. 26.03.2024
13.	Dextrose Injection IP 25% w/v	Dextrose Anhydrous IP 25gm, Water for injections IP q.s.	100ml	0.24 per ML	1557(E) dt. 26.03.2024
14.	Dextrose Injection IP 25% w/v	Dextrose Anhydrous IP 25gm, Water for injections IP q.s.	500ml	0.24 per ML	2289(E) dt. 14.06.2024

Agenda Item No. 4: Retail price fixation under Para 5 of DPCO, 2013 for "Each film coated tablet Contains: Atorvastatin Calcium IP equivalent to Atorvastatin 80 mg and Ezetimibe IP 10 mg" for M/s Windlas Biotech Ltd. (Plant-2) (Manufacturer) & M/s Intas Pharmaceuticals Ltd. (Marketer) (File No. 4231).

4.1 The Committee deliberated upon the matter and recommended the retail price for each film coated tablet Contains: Atorvastatin Calcium IP equivalent to Atorvastatin 80 mg and Ezetimibe IP 10 mg for M/s Windlas Biotech Ltd. (Plant-2) (Manufacturer) & M/s Intas Pharmaceuticals Ltd. (Marketer) at Rs.50.00 per tablet as below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each film coated tablet contains: Atorvastatin Calcium IP equivalent to Atorvastatin 80 mg, Ezetimibe IP 10 mg		
(a)	Ceiling price of Atorvastatin IP 80mg	Ceiling price [S.O. 4663 (E) dated 25.10.2023]	40.58
(b)	Retail price of Ezetimibe 10mg tablet	Retail Price based on February 2024 data	15.61
(c)	Less 20% of the lower of (a), (b) and (c) based on inference drawn from the Pronab Sen Committee Report		3.12
(d)	Worked out Retail Price excluding GST (a)+(b)-(c)		53.07
(e)	Claimed Retail price excluding GST		50.00
(f)	Recommended retail price excluding GST (lower of claimed or worked out price)		50.00

Agenda Item No. 5: Retail price fixation under Para 5 of DPCO, 2013 for Each Chewable tablet Contains: Famotidine IP 10 mg + Calcium Carbonate IP 800mg + Magnesium Hydroxide IP 165mg for M/s Pure and Cure Healthcare Pvt Ltd. (Manufacturer) & M/s Akumentis Healthcare Ltd (Marketer) (File No. 4179).

5.1 The Committee deliberated upon the matter and recommended the retail price for each Chewable tablet Contains: Famotidine IP 10 mg + Calcium Carbonate IP 800mg + Magnesium Hydroxide IP 165mg for M/s Pure and Cure Healthcare Pvt Ltd. (Manufacturer) & M/s Akumentis Healthcare Ltd (Marketer) at Rs.5.30 per tablet as below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each chewable tablet contains: Famotidine IP 10mg Calcium Carbonate IP 800mg Magnesium Hydroxide IP 165mg		
(a)	Derived retail price of Famotidine IP 10mg	Retail Price (as per the formula of Pronab Sen Committee) based on February, 2024 data **Note-1**	0.21

S. No.	Particulars	Source/Method	Amount (Rs.)
(b)	Derived retail price of Calcium carbonate 800mg tablet	Ceiling price [S.O. 1573 (E) dated 31.03.2023] (as per the formula of Pronab Sen Committee) **Note-2**	3.18
(c)	Derived Retail price of Magnesium Hydroxide 165 mg tablet (eq. to Elemental Magnesium 69.3mg)	Retail Price (as per the formula of Pronab Sen Committee) based on February, 2024 data **Note-3**	1.95
(d)	Less 20% of the lower of (a), (b) and (c) based on inference drawn from the Pronab Sen Committee Report		0.042
(e)	Worked out Retail Price excluding GST (a)+(b)+(c)-(d)		5.30
(f)	Claimed Retail price excluding GST		13.89
(g)	**Recommended retail price excluding GST (lower of claimed or worked out price)**		**5.30**

Note-1: Retail price of Famotidine 10 mg tablet as per the formula recommended in the Pronab Sen Committee report:

Derived retail price as per recommendation of Pronab Sen committee:
$P(s) = P^*[1+a.\{(s-s^*)/s^*\}]$
where, P(s) =Price ceiling of the strength s
P* = price ceiling for reference strength s*
s = strength in terms of API content
s* = reference strength
a= 0.8 for tablet / capsule and 0.7 for injectables.
The Retail Price of Famotidine 20 mg tablet based on February,2024 data = Rs. 0.35 per tablet (Excluding GST)
Derived retail price of Famotidine 10 mg tablet based on February,2024 data after applying the formula of Pronab Sen Committee
$= 0.35[1+0.80\{(10-20)/20\}]$
= Rs.0.21 per tablet (Excluding GST)

Note-2: Retail price of Calcium Carbonate 800 mg tablet as per the formula recommended in the Pronab Sen Committee report:

Derived retail price as per recommendation of Pronab Sen committee:
$P(s) = P^*[1+a.\{(s-s^*)/s^*\}]$
where, P(s) =Price ceiling of the strength s
P* = price ceiling for reference strength s*
s = strength in terms of API content
s* = reference strength
a= 0.8 for tablet / capsule and 0.7 for injectables.
The Ceiling Price of Calcium Carbonate 500 mg tablet as on February, 2024 = Rs. 2.15 per tablet (Excluding GST) [S.O. 1573(E) dated 31.03.2023]

Derived retail price of Calcium carbonate 800mg as on February,2024 after applying the formula of Pronab Sen Committee
= 2.15[1+0.80{(800-500)/500}]
= Rs.3.18 per tablet (Excluding GST)

Note 3: Retail price of Magnesium 165mg tablet as per the formula recommended in the Pronab Sen Committee report:

The calculation is as below: -
Derived retail price as per recommendation of Pronab Sen committee:
$P(s) = P^*[1+a.\{(s-s^*)/s^*\}]$
Where: P(s) =Price ceiling of the strength s
P* = price ceiling for reference strength s*
s = strength in terms of API content
s* = reference strength
a= 0.8 for tablet / capsule and 0.7 for injectables.

The Retail Price of Magnesium oxide 400mg eq. to 240mg of Elemental Magnesium (i.e. 61% of Elemental Magnesium) = Rs. 4.52 per tablet (Excluding GST) based on MAT/PTR of February 2024 .

The subject formulation contains 165mg of Magnesium hydroxide equivalent to 69.3 mg of Elemental Magnesium (i.e., 42% of Elemental Magnesium)

Derived retail price of Elemental Magnesium 69.3mg tablet as on February, 2024 after applying the formula of Pronab Sen Committee:
= 4.52[1+0.80{(69.3-240)/240}]
= Rs. 1.95 per tablet (excluding GST)

Agenda Item No. 6: Retail price fixation of Composition: Each 100ml contains: Potassium Chloride IP 150mg + Dextrose Monohydrate IP 5000mg + Sodium Chloride IP 900mg for M/s Otsuka Pharmaceuticals India Pvt Ltd (Manufacturer) & (Marketer) (F. No. 3936)

6.1 The committee recalled that the matter was earlier deliberated in 60th MDC held on 26.06.2024, 61st MDC held on 14.08.2024 wherein, the committee had recommended a price of Rs.45.51 per pack of 500 ml. However, the company represented against the price recommended by the committee. The recommendation of the 61st MDC, representation dated 27.08.2024 were discussed before the Authority in its 126th meeting held on 09.09.2024. and it was decided that the company may be asked to resubmit the application under Para 11(3).

6.2 The Committee further noted that subsequent to the decision of the Authority, the applicant vide letter dated 12.09.2024 requested that it may be granted separate price based on their initial application and accordingly, the matter was deliberated in 62nd meeting of the committee held on 26.09.2024 wherein the Committee directed the company to submit following documents and demonstrate their product

i. Test report of three consecutive batches for plastic granules used as per IP standards

ii. Detailed flow rate analysis of more than one bottle from each batch along with standard deviation, if any, in data
iii. Report on residual quantity after administration in respect of the IV fluids

6.3 The committee further noted that the company vide email dated 21.10.2024 submitted the documents regarding test report of plastic granules, protocol of flow rates and residual volume analysis and report of flow rate and residual analysis.

6.4 The Company demonstrated their product in the meeting and during the demonstration, the company was asked that plastic used in manufacture of their product conforms to which IP grade. The company said that they are using plastic as per the IP 2024. The Committee noted that there is no IP 2024. The Committee therefore directed the company to submit an undertaking about the IP grade plastic used for the container.

6.5 The Committee noted that the extracted quantity in each of the bottles for which test report has been submitted by the company is higher than standard volume i.e., 500 ML. It was also observed that the flow rate was non-uniform in the flow rate data provided by the company vide email dated 21.10.2024.

6.6 Accordingly, the Committee directed that the company to provide the reason for filing volume more than standard volume and also flow rate analysis data along with standard deviation.

Agenda Item No. 7: Retail price fixation of Composition: Each 100ml contains: Potassium Chloride IP 150mg + Dextrose Monohydrate IP 5000mg + Sodium Chloride IP 450mg for M/s Otsuka Pharmaceuticals India Pvt Ltd (Manufacturer) & (Marketer) (F. No. 3947)

7.1 The committee recalled that the matter was earlier deliberated in 60th MDC held on 26.06.2024, 61st MDC held on 14.08.2024 wherein, the committee had recommended a price of Rs.33.81 per pack of 500 ml. However, the company represented against the price recommended by the committee. The recommendation of the 61st MDC, representation dated 27.08.2024 were discussed before the Authority in its 126th meeting held on 09.09.2024. and it was decided that the company may be asked to resubmit the application under Para 11(3).

7.2 The Committee further noted that subsequent to the decision of the Authority, the applicant vide letter dated 12.09.2024 requested that it may be granted separate price based on their initial application and accordingly, the matter was deliberated in 62nd meeting of the committee held on 26.09.2024 wherein the Committee directed the company to submit following documents and demonstrate their product

i. Test report of three consecutive batches for plastic granules used as per IP standards
ii. Detailed flow rate analysis of more than one bottle from each batch along with standard deviation, if any, in data
iii. Report on residual quantity after administration in respect of the IV fluids

7.3 The committee further noted that the company vide email dated 21.10.2024 submitted the documents regarding test report of plastic granules, protocol of flow rates and residual volume analysis and report of flow rate and residual analysis.

7.4 The Company demonstrated their product in the meeting and during the demonstration, the company was asked that plastic used in manufacture of their product conforms to which IP grade. The company said that they are using plastic as per the IP 2024. The Committee noted that there is no IP 2024. The Committee therefore directed the company to submit an undertaking about the IP grade plastic used for the container.

7.5 The committee noted that the extracted quantity in each of the bottles for which test report has been submitted by the company is higher than standard volume i.e., 500 ML. It was also observed that the flow rate was non-uniform in the flow rate data provided by the company vide email dated 21.10.2024.

7.6 Accordingly, the committee directed that the company to provide the reason for filing volume more than standard volume and also flow rate analysis data along with standard deviation.

Agenda Item No. 8: Request for consideration of Price fixation for Multiple electrolytes and 5% Dextrose injection Type I USP for pack of non-glass container in plastic bottle with Euro Head and Non-PVC bag having special feature under Para 11(3) of DPCO, 2013 as applied by M/s Otsuka Pharmaceuticals India Pvt. Ltd. (Manufacturer & Marketer).

8.1 The Committee noted that M/s Otsuka Pharmaceuticals India Pvt. Ltd. has submitted a Form I application dated 01.08.2024 for the retail price fixation of a Multiple Electrolytes and 5% Dextrose Injection in non-glass containers in plastic bottles with Euro heads and non-PVC bags requesting for price fixation under Paragraph 11(3) of the DPCO 2013 claiming special features such as self-collapsibility, self sealability, no air vent requirement and minimized contamination risks during manufacture, infusion and admixing.

8.2 The Committee noted that the matter was earlier deliberated in 62nd meeting held on 26.09.2024 wherein the Committee directed the company to submit following documents and demonstrate their product,

i. Test report of three consecutive batches for plastic granules used as per IP standards
ii. Detailed flow rate analysis of more than one bottle from each batch along with standard deviation, if any, in data
iii. Report on residual quantity after administration in respect of the IV fluids

8.3 The committee further noted that the company vide email dated 21.10.2024 submitted the documents regarding test report of plastic granules, protocol of flow rates and residual volume analysis and report of flow rate and residual analysis.

8.4 The Company demonstrated their product in the meeting and during the demonstration, the company was asked that plastic used in manufacture of their product conforms to which IP grade. The company said that they are using plastic as per the IP

2024. The Committee noted that there is no IP 2024. The Committee therefore directed the company to submit an undertaking about the IP grade plastic used for the container.

8.5 The committee noted that the extracted quantity in each of the bottles/non PVC bags for which test report has been submitted by the company is higher than standard volume i.e., 500 ML. It was also observed that the flow rate was non-uniform in the flow rate data provided by the company vide email dated 21.10.2024.

8.6 Accordingly, the committee directed that the company to provide the reason for filing volume more than standard volume and also flow rate analysis data along with standard deviation.

The meeting ended with a vote of thanks to all.

28/10/24

(Rashmi Tahiliani)
Director (Pricing)

Copy to:
All members of the Committee.

Computation of Retail Price based on February, 2024 Data under Para 5 of DPCO, 2013

Ezetimibe 10mg tablet	Number of Companies consisting of Market Share of 1% & Above	2
	Sum of MAT value considered for price calculation (in Lakhs)	2,657.47
	Sum of PTR per unit considered for price calculation	26.92
	Number of Packs considered	2
	Average PTR	13.46
	Add : 16% Retailer Margin	2.15
	Retail Price (without local taxes)	15.61
	% Reduction with compared to Highest Price	0.74%

Minimum Price (Rs.)	13.36
Maximum Price (Rs.)	13.56
Average of all considered (Rs.)	13.46
Retail Price (Rs.)	15.61

								26,57,46,524	100%		M3		
S.No.	**पैक विवरण Pack Description**	**छाप BRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR**	**MAT(Rs.)**	**SKU wise MAT %**	**Brand wise MAT (ignoring O% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per unit (Rs.)**	**Price per unit (Rs.) Considered**
1	EZEDOC 10 MG TABLET 10	EZEDOC	LUPIN LTD	10 MG	10	TABLET	135.64	219377897	82.55%	82.55%	Y	13.56	13.56
2	EZENTIA 10 MG TABLET 10	EZENTIA	SUN PHARMA LABORATORIES LTD.	10 MG	10	TABLET	133.57	46368628	17.45%	17.45%	Y	13.36	13.36
		Rs. Per Tablet											
	Worked out Retail Price	15.61	Excluding GST										

Computation of Retail Price based on February, 2024 Data under Para 5 of DPCO, 2013

Famotidine 20mg tablet		
	Number of Companies consisting of Market Share of 1% & Above	4
	Sum of MAT value considered for price calculation (in Lakhs)	653.57
	Sum of PTR per unit considered for price calculation	1.18
	Number of Packs considered	4
	Average PTR	0.30
	Add : 16% Retailer Margin	0.05
	Retail Price (without local taxes)	0.35
	% Reduction with compared to Highest Price	6.25%

Minimum Price (Rs.)	0.26
Maximum Price (Rs.)	0.32
Average of all considered (Rs.)	0.30
Retail Price (Rs.)	0.35

														M3
								6,55,88,802	100%					
S.No.	**पैक विवरण Pack Description**	**छाप BRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR**	**MAT(Rs.)**	**SKU wise MAT %**	**Brandwise MAT (ignoring O% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per unit (Rs.)**	**Price per unit (Rs.) Considered**
1	FACID 20 MG TABLET 14	FACID	INTAS PHARMACEUTICALS LTD	20 MG	14	TABLET	2.68	389	0.00%	0.00%	N	0.19	
2	FAMOCER 20 MG TABLET 14	FAMOCER	ELDER PROJECTS LIMITED	20 MG	14	TABLET	2.73	5916	0.01%	0.01%	N	0.20	
3	FAMOCID 20 MG TABLET 14	FAMOCID	SUN PHARMA LABORATORIES LTD.	20 MG	14	TABLET	4.22	60949831	92.93%	92.93%	Y	0.30	0.30
4	FAMODIL 20 MG TABLET 14	FAMODIL	STADMED PVT. LTD	20 MG	14	TABLET	4.49	83330	0.13%	0.13%	N	0.32	
5	FAMODIN 20 MG TABLET 14	FAMODIN	CADILA PHARMACEUTICALS LTD	20 MG	14	TABLET	4.93	65563	0.10%	0.10%	N	0.35	
6	FAMONEXT 20 MG TABLET 14	FAMONEXT	CADILA PHARMACEUTICALS LTD	20 MG	14	TABLET	4.5	1209826	1.84%	1.84%	Y	0.32	0.32
7	FAMOTIDINE 20 MG TABLET 14	FAMOTIDINE	CIPLA LTD.	20 MG	14	TABLET	3.32	1069	0.00%	0.00%	N	0.24	
8	FM (CAPLET) 20 MG TABLET 14	FM (CAPLET)	CAPLET INDIA PRIVATE LIMITED	20 MG	14	TABLET	3.57	1050682	1.60%	1.60%	Y	0.26	0.26
9	PEPGARD 20 MG TABLET 10	PEPGARD	SHREYA LIFE SCIENCES PVT. LTD	20 MG	10	TABLET	25	32000	0.05%	0.05%	N	2.50	
10	TOPCID 20 MG TABLET 14	TOPCID	TORRENT PHARMACEUTICALS LTD.	20 MG	14	TABLET	4.2	2146969	3.27%	3.27%	Y	0.30	0.30
11	ACICON 20 MG TABLET 14	ACICON	ALEMBIC LTD	20 MG	14	TABLET	5.49	43228	0.07%	0.07%	N	0.39	
		Rs. Per Tablet											
	Worked out Retail Price	0.35	Excluding GST										

Computation of Retail Price based on February, 2024 Data under Para 5 of DPCO, 2013

Magnesium 400mg tablet	Number of Companies consisting of Market Share of 1% & Above	1
	Sum of MAT value considered for price calculation (in Lakhs)	14.25
	Sum of PTR per unit considered for price calculation	3.90
	Number of Packs considered	1
	Average PTR	3.90
	Add : 16% Retailer Margin	0.62
	Retail Price (without local taxes)	4.52
	% Reduction with compared to Highest Price	0.00%

Minimum Price (Rs.)	3.90
Maximum Price (Rs.)	3.90
Average of all considered (Rs.)	3.90
Retail Price (Rs.)	4.52

								14,24,577	100%			M3	
S.No.	**पैक विवरण Pack Description**	**छाप BRAND**	**कंपनी Company**	**Strength**	**Pack Size**	**Unit**	**PTR**	**MAT(Rs.)**	**SKU wise MAT %**	**Brandwise MAT (ignoring 0% MAT)**	**Qualify (Y/N) Y=Yes N=No**	**Price per unit (Rs.)**	**Price per unit (Rs.) Considered**
1	MAGINS TABLET 10	MAGINS	ANTHEM BIOPHARMA PVT LTD	400 MG	10	TABLET	39	1424577	100.00%	100.00%	Y	3.90	3.90
		Rs. Per Tablet											
	Worked out Retail Price	4.52	Excluding GST										